The prediction is this will stimulate the Internet of Bio-Nano Things leading to technological and clinical developments with high socioeconomic impact
Technology experts in Waterford are bidding to tackle one of the most aggressive forms of brain cancer using miniature, implantable devices. TSSG is Ireland’s only research hub involved in €6 million brain cancer project.
Brain cancer survival and recovery rates could be significantly improved as telecoms experts at Waterford Institute of Technology’s Telecommunications, Software and Systems Group (TSSG) partner with universities world-wide on the potentially life-changing GLADIATOR project.
Together, they’re developing miniature devices that interface with engineered cells, bio-nanomachines, to detect as well as treat the cancer from inside the brain. Engineering cells into bio-nanomachines involves the use of synthetic biology to design specific functions in living cells, and in this particular case, the secretion of molecules that can be used to detect and treat the tumour.
The devices, when implanted in the brain, will be controlled from an external wireless device that will collect information, which should enable a futuristic automated theranostic (therapeutic + diagnostic) solution for treating Glioblastoma Multiforme, a type of brain cancer that can kill within weeks.
GLADIATOR is a paradigm shift in Oncology, with the introduction of “bio-nano-machine diagnostics”. It will stimulate the greater use of the “Internet of Bio-Nano Things”, leading to technological and clinical developments with high socioeconomic impact, Principal Investigator and Director of Research at TSSG, Dr. Sasitharan Balasubramaniam predicts.
Molecular communication role for TSSG
TSSG’s specific role in GLADIATOR is to look at the molecular communications side of matters. Molecular Communications is the emerging discipline of exploring the transmission of encoded messages via engineered cells. This will allow artificial networks of bio-nanomachines to communicate, and when externally controlled, can be used to not only extract information on the status of the cancer but also manipulate it to affect its progression, Dr. Balasubramaniam said.
“The comprehensive theranostic solution for brain malignancies is set to be a significant medical breakthrough. Currently, highly complex malignancies such as brain tumours have a very grim prognosis, despite recent progress in their treatment and management,” he added.
Radical change for cancer monitoring
GLADIATOR’s mission is to radically and dramatically change cancer monitoring and therapy, TSSG’s Dr. Michael Barros said. “Surgery for this form of brain cancer is very traumatic as the cancer is embedded deep within the brain. GLADIATOR aims to use wireless signals to control implanted bio-nanomachine engineered cells within the brain for sensing and treatment, and to send signals back to an external computing device that will determine the next best course of action.
“Moreover, the innovative biological and nanotechnology-based innovations, development methods, computational and analytical tools advanced through GLADIATOR, are expected to have significant economic impact, since they can enter into particular market segments as indicated by global market projections and underlying drivers,” Dr. Barros explained.
“The project team will also examine the circuitry design, the power and communication requirements etc of these tiny implantable devices and how to interface to the bio-nanomachines that will interact with the cancer,” Dr Barros added.
Prolong patient survival
The €6 million Horizon 2020-funded project will substantially improve patient prognosis and prolong their survival, the GLADIATOR partners say.
GLADIATOR is already underway and the 4 year-long project sees ICT experts at TSSG working with six other vibrant academic centres across Cyprus (University of Cyprus), Finland (University of Oulu), Norway (Norwegian University of Science and Technology), Germany (Fraunhofer Institute for Biomedical Engineering), USA (Michigan State Univerity) and Japan (Osaka University) and a nano-biotechnology SME EPOS-IASIS from Cyprus.
It is expected that the project’s results will substantially improve patient prognosis and prolong survival by minimising recurrences and reducing drug toxicity. Extended life expectancy and productivity, shorter hospitalisations, and less personnel and caregiver involvement will also have a positive effect on the already overstrained Health Care Systems.
Specifically, GLADIATOR will provide, for the first time, a working prototype of a complete, autonomous and clinically applicable, nanonetwork-based, theranostic system based on the conceptual framework of Externally Controllable Molecular Communications (ECMC), Dr Barros revealed.
TSSG is a renowned hub of innovation in ICT and its role in molecular communications and health in particular, has been growing since 2008.